8/105 sources · 3 publishersUpdated Oct 8, 16:37 UTC
Coya completes enrollment for late-stage ALS study
Coya Therapeutics said it has finished recruiting 120 participants for its Phase 2/3 ALSTARS study of COYA 302 in amyotrophic lateral sclerosis. The company expects results from the blinded treatment portion in early Q2 2027. Separately, H.C. Wainwright maintained its Buy rating and $18.00 target after the enrollment update.
Why it matters
The completed enrollment starts the countdown to the study's planned data release, which could provide the first controlled efficacy evidence for COYA 302. H.C. Wainwright's maintained rating reflects its view of the development milestone.
Key facts
- 1Coya Therapeutics completed recruitment of 120 participants for the Phase 2/3 ALSTARS trial. investing.com
- 2The company expects topline ALSTARS results in early Q2 2027. tradingview.com
- 3ALSTARS is a randomized, placebo-controlled study assessing COYA 302 in ALS. investing.com
- 4H.C. Wainwright reiterated a Buy rating with a $18.00 price target following the enrollment announcement. investing.com
Summary written by AlphAI from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.